The estimated Net Worth of Vantage I, L.P.Versant Vant... is at least $9.55 Milhão dollars as of 3 June 2022. Vantage Vant owns over 750,000 units of Aprea Therapeutics stock worth over $358,978 and over the last 5 years Vantage sold APRE stock worth over $9,187,500.
Vantage has made over 3 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Vantage sold 750,000 units of APRE stock worth $9,187,500 on 3 June 2022.
The largest trade Vantage's ever made was selling 750,000 units of Aprea Therapeutics stock on 3 June 2022 worth over $9,187,500. On average, Vantage trades about 121,212 units every 88 days since 2019. As of 3 June 2022 Vantage still owns at least 111,484 units of Aprea Therapeutics stock.
You can see the complete history of Vantage Vant stock trades at the bottom of the page.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant..., eJohn B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: